ASH 2013
American Society of Hematology Annual Meeting
Interviews and expert commentary from ASH 2013 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology
Idelalisib: new targeted therapy improves outlook for patients with chronic lymphocytic leukaemia
NEW ORLEANS—A new oral tyrosine kinase inhibitor drug — idelalisib — has proved effective — and to have low toxicity — in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weil
24 January 2014
0:00
Audio Journal of Oncology
First effective treatment for “orphan disease’: Anti I/L 6 antibody brings remissions in Multicentric Castleman’s Disease
The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease — MCD — could soon be treatable following findings announced at the American Society of Hematology annual meeting
21 January 2014
0:00